The GLP is committed to full transparency. Download and review our 2019 Annual Report

Glyphosate-cancer trials postponed while Bayer, plaintiffs negotiate potential $8-$12 billion settlement

| | December 9, 2019

The GLP posts this article or excerpt as part of a daily curated selection of biotechnology-related news, opinion and analysis.

Germany’s Bayer has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

The company, which is facing 42,700 U.S. plaintiffs, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion.

Read full, original article: Bayer reaches agreement to postpone more glyphosate lawsuits for settlement talks

Related article:  Anti-GMO activists use FOIA to bully mother-scientist nutrition and lactation expert
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend